Nicholas Turner, MD, PhD
A blood test that detects early changes in circulating tumor DNA (ctDNA) may provide an earlier indication of whether patients with hormone receptor–positive, HER2-negative breast cancer are responding to the CDK4/6 inhibitor palbociclib (Ibrance), according to findings published in Nature Communications.
In the United States, palbociclib is approved by the FDA for the treatment of patients with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women, or fulvestrant in women with disease progression following endocrine therapy.
O’Leary B, Hrebien S, Morden JP, et al. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer [published online March 1, 2018]. Nat Commun. doi:10.1038/s41467-018-03215-x.
... to read the full story